Stockholm, August 16, 2007
21-MONTH FINDINGS FROM DIAMYD® TYPE 1 DIABETES TRIAL TO BE PRESENTED AT AN INTERNATIONAL DIABETES CONFERENCE IN BERLIN
Press Release, Stockholm, Sweden, August 16, 2007 - Diamyd Medical AB
(www.omxgroup.com, ticker: DIAM B; www.otcqx.com, ticker DMYDY)
Diamyd Medical announced today that preliminary findings from a 21-month follow-up analysis of the previously reported successful Phase II type 1 diabetes trial will be presented at the annual ISPAD (International Society for Pediatric and Adolescent Diabetes) meeting in Berlin, Germany, the 26th
of September, 2007.
The trial is designed to investigate the efficacy and safety of the Diamyd® vaccine in 70 children with recent onset type 1 diabetes. The children were treated with two injections of Diamyd® or placebo. As previously reported, 15 months after treatment, the Diamyd® group showed significantly higher meal stimulated insulin levels than the placebo group. Diamyd®-treated patients also showed a clear favorable immune response.
The presentation at the ISPAD meeting in September will be made by Professor Johnny Ludvigsson, Linkoping University Hospital, Sweden, the principal investigator of the study.
In a separate presentation, additional immunological data from the type 1 diabetes study, after 15 months of follow-up, will be presented by Professor Ludvigsson´s team at the annual EASD (European Association for the Study of Diabetes) meeting in Amsterdam, the Netherlands, the 18th of September 2007.
As previously reported, Diamyd Medical is conducting partnership discussions while preparing its international Phase III program for type 1 diabetes.
About Diamyd Medical:
Diamyd Medical is a life science company developing treatments for diabetes and its complications. The company´s furthest developed project is the GAD-based drug Diamyd® for autoimmune diabetes. Diamyd® has demonstrated significant and positive results in phase II clinical trials in Sweden.
GAD65, a major autoantigen in autoimmune diabetes, is the active substance in Diamyd®. GAD65 is also an enzyme that converts the excitatory neurotransmitter glutamate to the inhibitory transmitter GABA. In this context GAD may have an important role not only in diabetes, but also in several central nervous system-related diseases. Diamyd Medical has an exclusive worldwide license from the University of California at Los Angeles regarding the therapeutic use of the GAD65 gene.
Diamyd Medical has sublicensed its UCLA GAD65 Composition of Matter license to Neurologix, Inc. in Fort Lee, New Jersey for treatment of Parkinson´s disease with an AAV-vector.
Other projects comprise drug development within gene therapy using the exclusively licensed and patent protected Nerve Targeted Drug Delivery System (NTDDS). The company´s lead gene therapy projects include using Enkephalin and GAD for chronic pain, e.g., diabetes pain or cancer pain. All projects in this field are currently in preclinical phases.
Diamyd Medical has offices in Stockholm (Sweden) and in Pittsburgh (USA). The Diamyd Medical share is quoted on the Stockholm Nordic Exchange in Sweden (ticker symbol: DIAM B) and on the OTCQX-list in the US (ticker symbol: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available at www.diamyd.com.
For further information, please contact:
CEO and President
Tel: +46 8 661 0026
Tel: +1 412 770 1310
For media contact in the US, please contact:
Gregory Tiberend, Executive Vice President
Richard Lewis Communications, Inc.
Tel: +1 212 827 0020
Diamyd Medical AB (publ). Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 8 661 00 26, fax: +46 8 661 63 68 or E-mail: firstname.lastname@example.org. VATno: SE556530-142001.
Disclaimer: This document contains certain "statements" relating to present understandings, future events and future performance, including statements relating to the progress, timing and completion of our research, development and clinical trials; our ability to market, commercialize and achieve market acceptance for product candidates; and our current and future strategic partner relationships. These statements can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Diamyd Medical undertakes no obligation to publicly update such statements, whether because of new information, future events or otherwise, nor does Diamyd Medical give any guarantees that the statements, given or implied, are correct. This document is a translation from the Swedish original. No guarantees are made that the translation is free from errors.